AG真人官方

STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANET
  4. [Form 4] Arista Networks Insider Trading Activity

[Form 4] Arista Networks Insider Trading Activity

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Schedule 13D/A Amendment 10 highlights: Three related investors鈥�Parag Saxena, Vedanta Partners, LLC and Vedanta Associates, L.P.鈥攗pdated their beneficial ownership in Reviva Pharmaceuticals Holdings, Inc. (RVPH) as of the event date 27 June 2025 and filing date 1 July 2025.

  • Parag Saxena now reports 6,259,806 shares, or 8.7 % of RVPH鈥檚 68,003,613 outstanding shares. His stake includes 21,400 vested stock options and a mix of common shares, warrants and pre-funded warrants.
  • Vedanta Partners is shown with 5,367,069 shares, equating to 7.5 % of the class.
  • Vedanta Associates reports 3,408,401 shares, or 4.8 %. Because the holding fell below 5 %, Item 5(e) states the entity ceased to be a 5 % beneficial owner on 27 June 2025.
  • No transactions were effected in the past 60 days; changes arise from share count dynamics and warrant/option calculations. Certain warrants are subject to a 4.99 % blocker that limits exercise to avoid crossing ownership thresholds.

Implications for investors: The overall 鈥淰edanta group鈥� remains a significant insider bloc (>8 %) capable of influencing corporate actions. However, one vehicle dropping below 5 % reduces mandatory reporting frequency for that entity and may signal distribution of ownership or passive dilution. The filing contains no operational, financial or strategic updates from RVPH itself.

Punti salienti dell'emendamento 10 al Schedule 13D/A: Tre investitori correlati鈥�Parag Saxena, Vedanta Partners, LLC e Vedanta Associates, L.P.鈥攈anno aggiornato la loro partecipazione azionaria in Reviva Pharmaceuticals Holdings, Inc. (RVPH) alla data dell'evento 27 giugno 2025 e alla data di deposito 1 luglio 2025.

  • Parag Saxena ora detiene 6.259.806 azioni, pari all鈥�8,7% delle 68.003.613 azioni in circolazione di RVPH. La sua partecipazione include 21.400 opzioni azionarie maturate e una combinazione di azioni ordinarie, warrant e warrant prefinanziati.
  • Vedanta Partners risulta con 5.367.069 azioni, equivalenti al 7,5% della categoria.
  • Vedanta Associates dichiara 3.408.401 azioni, pari al 4,8%. Poich茅 la partecipazione 猫 scesa sotto il 5%, il punto 5(e) indica che l'entit脿 ha cessato di essere un azionista beneficiario del 5% il 27 giugno 2025.
  • Negli ultimi 60 giorni non sono state effettuate transazioni; le variazioni derivano da dinamiche nel conteggio delle azioni e nel calcolo di warrant/opzioni. Alcuni warrant sono soggetti a un blocco del 4,99% che limita l'esercizio per evitare di superare le soglie di propriet脿.

Implicazioni per gli investitori: Il gruppo complessivo 鈥淰edanta鈥� rimane un blocco interno significativo (>8%) con capacit脿 di influenzare le azioni societarie. Tuttavia, il calo di una delle entit脿 sotto il 5% riduce la frequenza degli obblighi di comunicazione per quella entit脿 e potrebbe indicare una distribuzione della propriet脿 o una diluizione passiva. Il deposito non contiene aggiornamenti operativi, finanziari o strategici da parte di RVPH stessa.

Aspectos destacados de la enmienda 10 al Schedule 13D/A: Tres inversores relacionados鈥�Parag Saxena, Vedanta Partners, LLC y Vedanta Associates, L.P.鈥攁ctualizaron su propiedad beneficiaria en Reviva Pharmaceuticals Holdings, Inc. (RVPH) con fecha del evento 27 de junio de 2025 y fecha de presentaci贸n 1 de julio de 2025.

  • Parag Saxena reporta ahora 6,259,806 acciones, equivalentes al 8.7% de las 68,003,613 acciones en circulaci贸n de RVPH. Su participaci贸n incluye 21,400 opciones de acciones ya adquiridas y una combinaci贸n de acciones comunes, warrants y warrants prefinanciados.
  • Vedanta Partners aparece con 5,367,069 acciones, que representan el 7.5% de la clase.
  • Vedanta Associates reporta 3,408,401 acciones, o el 4.8%. Debido a que la participaci贸n cay贸 por debajo del 5%, el punto 5(e) indica que la entidad 诲别箩贸 de ser un propietario beneficiario del 5% el 27 de junio de 2025.
  • No se realizaron transacciones en los 煤ltimos 60 d铆as; los cambios provienen de din谩micas en el conteo de acciones y c谩lculos de warrants/opciones. Algunos warrants est谩n sujetos a un bloqueo del 4.99% que limita su ejercicio para evitar superar los umbrales de propiedad.

Implicaciones para los inversores: El grupo 鈥淰edanta鈥� en conjunto sigue siendo un bloque interno significativo (>8%) capaz de influir en las acciones corporativas. Sin embargo, que una entidad baje del 5% reduce la frecuencia de los informes obligatorios para esa entidad y puede indicar una distribuci贸n de la propiedad o una diluci贸n pasiva. La presentaci贸n no contiene actualizaciones operativas, financieras o estrat茅gicas de RVPH.

Schedule 13D/A 靾橃爼鞎� 10鞚� 欤检殧 雮挫毄: 靹� 氇呾潣 甏�霠� 韴瀽鞛愨��Parag Saxena, Vedanta Partners, LLC, 攴鸽Μ瓿� Vedanta Associates, L.P.鈥旉皜 2025雲� 6鞗� 27鞚� 旮办 氚� 2025雲� 7鞗� 1鞚� 鞝滌稖鞚检瀽搿� Reviva Pharmaceuticals Holdings, Inc. (RVPH)鞚� 鞁れ 靻岇湢 歆�攵勳潉 臧膘嫚頄堨姷雼堧嫟.

  • Parag Saxena电� 順勳灛 RVPH鞚� 齑� 68,003,613欤� 欷� 6,259,806欤�, 歃� 8.7%毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 攴胳潣 歆�攵勳棎电� 21,400欤检潣 頄夓偓 臧�電ロ暅 鞀ろ啞鞓奠厴瓿� 氤错喌欤�, 鞗岆煱韸�, 靹犾旮� 鞗岆煱韸戈皜 順柬暕霅橃柎 鞛堨姷雼堧嫟.
  • Vedanta Partners电� 5,367,069欤�搿�, 鞝勳泊 欤检嫕鞚� 7.5%毳� 彀頃╇媹雼�.
  • Vedanta Associates电� 3,408,401欤�毳� 氤挫湢頃橃棳 4.8%毳� 彀頃╇媹雼�. 氤挫湢 歆�攵勳澊 5% 氙鸽鞙茧 霒柎歆愳棎 霐半澕 5(e)頃棎 霐半ゴ氅� 頃措嫻 氩曥澑鞚� 2025雲� 6鞗� 27鞚茧秬搿� 5% 鞚挫儊鞚� 鞁れ 靻岇湢欤� 歆�鞙勲ゼ 靸侅嫟頄堨姷雼堧嫟.
  • 斓滉芳 60鞚缄皠 瓯半灅电� 鞐嗢棃鞙茧┌, 氤�霃欖潃 欤检嫕 靾� 氤�頇旍檧 鞗岆煱韸�/鞓奠厴 瓿勳偘鞐� 霐半ジ 瓴冹瀰雼堧嫟. 鞚茧秬 鞗岆煱韸傅鐢 靻岇湢 歆�攵� 頃滊弰毳� 齑堦臣頃橃 鞎婋弰搿� 4.99%鞚� 彀嫧 鞛レ箻臧� 鞝侅毄霅橃柎 頄夓偓 鞝滍暅鞚� 鞛堨姷雼堧嫟.

韴瀽鞛愳棎 雽�頃� 鞁滌偓鞝�: 鞝勳泊 鈥淰edanta 攴鸽９鈥濎潃 鞐爠頌� 8% 鞚挫儊鞙茧 欷戩殧頃� 雮措秬鞛� 攴鸽９鞙茧靹� 旮办梾 頇滊彊鞐� 鞓來枼鞚� 氙胳範 靾� 鞛堨姷雼堧嫟. 雼る, 頃� 氩曥澑鞚� 氤挫湢 歆�攵勳澊 5% 氙鸽鞙茧 霒柎歆�氅挫劀 頃措嫻 氩曥澑鞚� 鞚橂 氤搓碃 牍堧弰臧� 欷勳柎霌り碃, 歆�攵� 攵勳偘 霕惖鐢 靾橂彊鞝� 頋劃 臧�電レ劚鞚� 鞁滌偓頃� 靾� 鞛堨姷雼堧嫟. 鞝滌稖 靹滊鞐惖鐢 RVPH 鞛愳泊鞚� 鞖挫榿, 鞛 霕惖鐢 鞝勲灥鞝� 鞐呺嵃鞚错姼电� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.

Points cl茅s de l鈥檃mendement 10 au Schedule 13D/A : Trois investisseurs li茅s鈥�Parag Saxena, Vedanta Partners, LLC et Vedanta Associates, L.P.鈥攐nt mis 脿 jour leur propri茅t茅 b茅n茅ficiaire dans Reviva Pharmaceuticals Holdings, Inc. (RVPH) 脿 la date de l鈥櫭﹙茅nement du 27 juin 2025 et 脿 la date de d茅p么t du 1er juillet 2025.

  • Parag Saxena 诲茅肠濒补谤别 d茅sormais 6 259 806 actions, soit 8,7 % des 68 003 613 actions en circulation de RVPH. Sa participation comprend 21 400 options d鈥檃chat d鈥檃ctions acquises et un m茅lange d鈥檃ctions ordinaires, de bons de souscription et de bons de souscription pr茅financ茅s.
  • Vedanta Partners est indiqu茅 avec 5 367 069 actions, repr茅sentant 7,5 % de la cat茅gorie.
  • Vedanta Associates 诲茅肠濒补谤别 3 408 401 actions, soit 4,8 %. 脡tant donn茅 que la d茅tention est pass茅e sous la barre des 5 %, l鈥檃rticle 5(e) pr茅cise que l鈥檈ntit茅 a 肠别蝉蝉茅 d鈥櫭猼re un propri茅taire b茅n茅ficiaire 脿 5 % le 27 juin 2025.
  • Aucune transaction n鈥檃 茅t茅 effectu茅e au cours des 60 derniers jours ; les changements r茅sultent de la dynamique du nombre d鈥檃ctions et du calcul des bons/options. Certains bons sont soumis 脿 un verrouillage 脿 4,99 % qui limite leur exercice afin d鈥櫭﹙iter de d茅passer les seuils de propri茅t茅.

Implications pour les investisseurs : Le 芦 groupe Vedanta 禄 dans son ensemble reste un bloc d鈥檌niti茅s important (>8 %) capable d鈥檌nfluencer les actions de la soci茅t茅. Toutefois, la baisse d鈥檜ne entit茅 sous 5 % r茅duit la fr茅quence des obligations de d茅claration pour cette entit茅 et peut indiquer une r茅partition de la propri茅t茅 ou une dilution passive. Le d茅p么t ne contient aucune mise 脿 jour op茅rationnelle, financi猫re ou strat茅gique de la part de RVPH elle-m锚me.

Wesentliche Punkte der 脛nderung 10 zum Schedule 13D/A: Drei verbundene Investoren鈥�Parag Saxena, Vedanta Partners, LLC und Vedanta Associates, L.P.鈥攈aben ihre wirtschaftliche Eigent眉merschaft an Reviva Pharmaceuticals Holdings, Inc. (RVPH) zum Ereignisdatum 27. Juni 2025 und Einreichungsdatum 1. Juli 2025 aktualisiert.

  • Parag Saxena meldet nun 6.259.806 Aktien, das entspricht 8,7 % der 68.003.613 ausstehenden Aktien von RVPH. Sein Anteil umfasst 21.400 ausge眉bte Aktienoptionen sowie eine Mischung aus Stammaktien, Warrants und vorfinanzierten Warrants.
  • Vedanta Partners wird mit 5.367.069 Aktien gef眉hrt, was 7,5 % der Klasse entspricht.
  • Vedanta Associates berichtet 3.408.401 Aktien, also 4,8 %. Da der Anteil unter 5 % gefallen ist, gibt Punkt 5(e) an, dass die Einheit am 27. Juni 2025 keine 5-%-Beteiligung mehr h盲lt.
  • In den letzten 60 Tagen wurden keine Transaktionen durchgef眉hrt; 脛nderungen ergeben sich aus der Dynamik der Aktienanzahl und der Berechnung von Warrants/Optionen. Einige Warrants unterliegen einer 4,99-%-Blockade, die die Aus眉bung einschr盲nkt, um eine 脺berschreitung der Eigentumsschwellen zu vermeiden.

Auswirkungen f眉r Investoren: Die gesamte 鈥濾edanta-Gruppe鈥� bleibt ein bedeutender Insiderblock (>8 %), der in der Lage ist, Unternehmensentscheidungen zu beeinflussen. Allerdings verringert das Unterschreiten der 5-%-Marke durch eine Einheit die H盲ufigkeit der Meldepflichten f眉r diese Einheit und kann auf eine Verteilung der Eigentumsverh盲ltnisse oder passive Verw盲sserung hinweisen. Die Einreichung enth盲lt keine operativen, finanziellen oder strategischen Updates von RVPH selbst.

Positive
  • Continued significant insider ownership鈥擯arag Saxena holds 8.7 %, suggesting ongoing commitment to RVPH.
  • No recent insider sales reported, implying stability in the shareholder base.
Negative
  • Vedanta Associates' stake fell below 5 %, potentially signaling dilution or partial exit.
  • Minor discrepancy between 6,259,806 and 6,269,806 share counts within the filing, which could cause confusion.

Insights

TL;DR 鈥� Insider group still strong; one fund dips below 5 %.

The amendment primarily refreshes ownership data. Saxena and related funds collectively continue to own a meaningful 8-9 % stake, maintaining influence and signalling ongoing confidence. Vedanta Associates鈥� drop to 4.8 % removes it from 5 %-plus disclosure status, but group control is essentially unchanged. No share sales are disclosed over the last 60 days, so the percentage shift is most likely dilution-driven rather than a disposal. From a valuation perspective the filing is neutral; it neither injects capital nor alters fundamentals, yet it reassures that a long-term insider remains committed.

TL;DR 鈥� Governance impact minor; reporting compliance intact.

The amendment satisfies Section 13(d) obligations after a threshold change. While Vedanta Associates exits the >5 % bracket, Saxena still files as a control person. Investors should note the 4.99 % blocker on certain warrants, limiting sudden voting power spikes. No coordinated 鈥済roup鈥� box was ticked, reducing takeover-speculation risk. Overall governance impact is limited and does not trigger anti-dilution or poison-pill provisions.

Punti salienti dell'emendamento 10 al Schedule 13D/A: Tre investitori correlati鈥�Parag Saxena, Vedanta Partners, LLC e Vedanta Associates, L.P.鈥攈anno aggiornato la loro partecipazione azionaria in Reviva Pharmaceuticals Holdings, Inc. (RVPH) alla data dell'evento 27 giugno 2025 e alla data di deposito 1 luglio 2025.

  • Parag Saxena ora detiene 6.259.806 azioni, pari all鈥�8,7% delle 68.003.613 azioni in circolazione di RVPH. La sua partecipazione include 21.400 opzioni azionarie maturate e una combinazione di azioni ordinarie, warrant e warrant prefinanziati.
  • Vedanta Partners risulta con 5.367.069 azioni, equivalenti al 7,5% della categoria.
  • Vedanta Associates dichiara 3.408.401 azioni, pari al 4,8%. Poich茅 la partecipazione 猫 scesa sotto il 5%, il punto 5(e) indica che l'entit脿 ha cessato di essere un azionista beneficiario del 5% il 27 giugno 2025.
  • Negli ultimi 60 giorni non sono state effettuate transazioni; le variazioni derivano da dinamiche nel conteggio delle azioni e nel calcolo di warrant/opzioni. Alcuni warrant sono soggetti a un blocco del 4,99% che limita l'esercizio per evitare di superare le soglie di propriet脿.

Implicazioni per gli investitori: Il gruppo complessivo 鈥淰edanta鈥� rimane un blocco interno significativo (>8%) con capacit脿 di influenzare le azioni societarie. Tuttavia, il calo di una delle entit脿 sotto il 5% riduce la frequenza degli obblighi di comunicazione per quella entit脿 e potrebbe indicare una distribuzione della propriet脿 o una diluizione passiva. Il deposito non contiene aggiornamenti operativi, finanziari o strategici da parte di RVPH stessa.

Aspectos destacados de la enmienda 10 al Schedule 13D/A: Tres inversores relacionados鈥�Parag Saxena, Vedanta Partners, LLC y Vedanta Associates, L.P.鈥攁ctualizaron su propiedad beneficiaria en Reviva Pharmaceuticals Holdings, Inc. (RVPH) con fecha del evento 27 de junio de 2025 y fecha de presentaci贸n 1 de julio de 2025.

  • Parag Saxena reporta ahora 6,259,806 acciones, equivalentes al 8.7% de las 68,003,613 acciones en circulaci贸n de RVPH. Su participaci贸n incluye 21,400 opciones de acciones ya adquiridas y una combinaci贸n de acciones comunes, warrants y warrants prefinanciados.
  • Vedanta Partners aparece con 5,367,069 acciones, que representan el 7.5% de la clase.
  • Vedanta Associates reporta 3,408,401 acciones, o el 4.8%. Debido a que la participaci贸n cay贸 por debajo del 5%, el punto 5(e) indica que la entidad 诲别箩贸 de ser un propietario beneficiario del 5% el 27 de junio de 2025.
  • No se realizaron transacciones en los 煤ltimos 60 d铆as; los cambios provienen de din谩micas en el conteo de acciones y c谩lculos de warrants/opciones. Algunos warrants est谩n sujetos a un bloqueo del 4.99% que limita su ejercicio para evitar superar los umbrales de propiedad.

Implicaciones para los inversores: El grupo 鈥淰edanta鈥� en conjunto sigue siendo un bloque interno significativo (>8%) capaz de influir en las acciones corporativas. Sin embargo, que una entidad baje del 5% reduce la frecuencia de los informes obligatorios para esa entidad y puede indicar una distribuci贸n de la propiedad o una diluci贸n pasiva. La presentaci贸n no contiene actualizaciones operativas, financieras o estrat茅gicas de RVPH.

Schedule 13D/A 靾橃爼鞎� 10鞚� 欤检殧 雮挫毄: 靹� 氇呾潣 甏�霠� 韴瀽鞛愨��Parag Saxena, Vedanta Partners, LLC, 攴鸽Μ瓿� Vedanta Associates, L.P.鈥旉皜 2025雲� 6鞗� 27鞚� 旮办 氚� 2025雲� 7鞗� 1鞚� 鞝滌稖鞚检瀽搿� Reviva Pharmaceuticals Holdings, Inc. (RVPH)鞚� 鞁れ 靻岇湢 歆�攵勳潉 臧膘嫚頄堨姷雼堧嫟.

  • Parag Saxena电� 順勳灛 RVPH鞚� 齑� 68,003,613欤� 欷� 6,259,806欤�, 歃� 8.7%毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 攴胳潣 歆�攵勳棎电� 21,400欤检潣 頄夓偓 臧�電ロ暅 鞀ろ啞鞓奠厴瓿� 氤错喌欤�, 鞗岆煱韸�, 靹犾旮� 鞗岆煱韸戈皜 順柬暕霅橃柎 鞛堨姷雼堧嫟.
  • Vedanta Partners电� 5,367,069欤�搿�, 鞝勳泊 欤检嫕鞚� 7.5%毳� 彀頃╇媹雼�.
  • Vedanta Associates电� 3,408,401欤�毳� 氤挫湢頃橃棳 4.8%毳� 彀頃╇媹雼�. 氤挫湢 歆�攵勳澊 5% 氙鸽鞙茧 霒柎歆愳棎 霐半澕 5(e)頃棎 霐半ゴ氅� 頃措嫻 氩曥澑鞚� 2025雲� 6鞗� 27鞚茧秬搿� 5% 鞚挫儊鞚� 鞁れ 靻岇湢欤� 歆�鞙勲ゼ 靸侅嫟頄堨姷雼堧嫟.
  • 斓滉芳 60鞚缄皠 瓯半灅电� 鞐嗢棃鞙茧┌, 氤�霃欖潃 欤检嫕 靾� 氤�頇旍檧 鞗岆煱韸�/鞓奠厴 瓿勳偘鞐� 霐半ジ 瓴冹瀰雼堧嫟. 鞚茧秬 鞗岆煱韸傅鐢 靻岇湢 歆�攵� 頃滊弰毳� 齑堦臣頃橃 鞎婋弰搿� 4.99%鞚� 彀嫧 鞛レ箻臧� 鞝侅毄霅橃柎 頄夓偓 鞝滍暅鞚� 鞛堨姷雼堧嫟.

韴瀽鞛愳棎 雽�頃� 鞁滌偓鞝�: 鞝勳泊 鈥淰edanta 攴鸽９鈥濎潃 鞐爠頌� 8% 鞚挫儊鞙茧 欷戩殧頃� 雮措秬鞛� 攴鸽９鞙茧靹� 旮办梾 頇滊彊鞐� 鞓來枼鞚� 氙胳範 靾� 鞛堨姷雼堧嫟. 雼る, 頃� 氩曥澑鞚� 氤挫湢 歆�攵勳澊 5% 氙鸽鞙茧 霒柎歆�氅挫劀 頃措嫻 氩曥澑鞚� 鞚橂 氤搓碃 牍堧弰臧� 欷勳柎霌り碃, 歆�攵� 攵勳偘 霕惖鐢 靾橂彊鞝� 頋劃 臧�電レ劚鞚� 鞁滌偓頃� 靾� 鞛堨姷雼堧嫟. 鞝滌稖 靹滊鞐惖鐢 RVPH 鞛愳泊鞚� 鞖挫榿, 鞛 霕惖鐢 鞝勲灥鞝� 鞐呺嵃鞚错姼电� 韽暔霅橃柎 鞛堨 鞎婌姷雼堧嫟.

Points cl茅s de l鈥檃mendement 10 au Schedule 13D/A : Trois investisseurs li茅s鈥�Parag Saxena, Vedanta Partners, LLC et Vedanta Associates, L.P.鈥攐nt mis 脿 jour leur propri茅t茅 b茅n茅ficiaire dans Reviva Pharmaceuticals Holdings, Inc. (RVPH) 脿 la date de l鈥櫭﹙茅nement du 27 juin 2025 et 脿 la date de d茅p么t du 1er juillet 2025.

  • Parag Saxena 诲茅肠濒补谤别 d茅sormais 6 259 806 actions, soit 8,7 % des 68 003 613 actions en circulation de RVPH. Sa participation comprend 21 400 options d鈥檃chat d鈥檃ctions acquises et un m茅lange d鈥檃ctions ordinaires, de bons de souscription et de bons de souscription pr茅financ茅s.
  • Vedanta Partners est indiqu茅 avec 5 367 069 actions, repr茅sentant 7,5 % de la cat茅gorie.
  • Vedanta Associates 诲茅肠濒补谤别 3 408 401 actions, soit 4,8 %. 脡tant donn茅 que la d茅tention est pass茅e sous la barre des 5 %, l鈥檃rticle 5(e) pr茅cise que l鈥檈ntit茅 a 肠别蝉蝉茅 d鈥櫭猼re un propri茅taire b茅n茅ficiaire 脿 5 % le 27 juin 2025.
  • Aucune transaction n鈥檃 茅t茅 effectu茅e au cours des 60 derniers jours ; les changements r茅sultent de la dynamique du nombre d鈥檃ctions et du calcul des bons/options. Certains bons sont soumis 脿 un verrouillage 脿 4,99 % qui limite leur exercice afin d鈥櫭﹙iter de d茅passer les seuils de propri茅t茅.

Implications pour les investisseurs : Le 芦 groupe Vedanta 禄 dans son ensemble reste un bloc d鈥檌niti茅s important (>8 %) capable d鈥檌nfluencer les actions de la soci茅t茅. Toutefois, la baisse d鈥檜ne entit茅 sous 5 % r茅duit la fr茅quence des obligations de d茅claration pour cette entit茅 et peut indiquer une r茅partition de la propri茅t茅 ou une dilution passive. Le d茅p么t ne contient aucune mise 脿 jour op茅rationnelle, financi猫re ou strat茅gique de la part de RVPH elle-m锚me.

Wesentliche Punkte der 脛nderung 10 zum Schedule 13D/A: Drei verbundene Investoren鈥�Parag Saxena, Vedanta Partners, LLC und Vedanta Associates, L.P.鈥攈aben ihre wirtschaftliche Eigent眉merschaft an Reviva Pharmaceuticals Holdings, Inc. (RVPH) zum Ereignisdatum 27. Juni 2025 und Einreichungsdatum 1. Juli 2025 aktualisiert.

  • Parag Saxena meldet nun 6.259.806 Aktien, das entspricht 8,7 % der 68.003.613 ausstehenden Aktien von RVPH. Sein Anteil umfasst 21.400 ausge眉bte Aktienoptionen sowie eine Mischung aus Stammaktien, Warrants und vorfinanzierten Warrants.
  • Vedanta Partners wird mit 5.367.069 Aktien gef眉hrt, was 7,5 % der Klasse entspricht.
  • Vedanta Associates berichtet 3.408.401 Aktien, also 4,8 %. Da der Anteil unter 5 % gefallen ist, gibt Punkt 5(e) an, dass die Einheit am 27. Juni 2025 keine 5-%-Beteiligung mehr h盲lt.
  • In den letzten 60 Tagen wurden keine Transaktionen durchgef眉hrt; 脛nderungen ergeben sich aus der Dynamik der Aktienanzahl und der Berechnung von Warrants/Optionen. Einige Warrants unterliegen einer 4,99-%-Blockade, die die Aus眉bung einschr盲nkt, um eine 脺berschreitung der Eigentumsschwellen zu vermeiden.

Auswirkungen f眉r Investoren: Die gesamte 鈥濾edanta-Gruppe鈥� bleibt ein bedeutender Insiderblock (>8 %), der in der Lage ist, Unternehmensentscheidungen zu beeinflussen. Allerdings verringert das Unterschreiten der 5-%-Marke durch eine Einheit die H盲ufigkeit der Meldepflichten f眉r diese Einheit und kann auf eine Verteilung der Eigentumsverh盲ltnisse oder passive Verw盲sserung hinweisen. Die Einreichung enth盲lt keine operativen, finanziellen oder strategischen Updates von RVPH selbst.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ullal Jayshree
(Last) (First) (Middle)
5453 GREAT AMERICA PARKWAY
(Street)
SANTA CLARA CA 95054
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Arista Networks, Inc. [ ANET ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
President and CEO
3. Date of Earliest Transaction (Month/Day/Year)
06/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/27/2025 S(1) 223 D $101.9921(2) 103,385 D
Common Stock 06/27/2025 S(1) 241 D $101.9921(2) 6,368,849 I By Trust for Child 1(3)
Common Stock 06/27/2025 S(1) 241 D $101.9921(2) 6,368,849 I By Trust for Child 2(3)
Common Stock 06/27/2025 S(1) 20 D $101.9921(2) 38,756 I By Trust for Nephew(4)
Common Stock 06/27/2025 S(1) 20 D $101.9921(2) 38,756 I By Trust for Niece(4)
Common Stock 06/27/2025 S(1) 1,271 D $101.9921(2) 24,418,658 I by Trust(5)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The exercises and/or sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 13, 2024.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $101.99 to $102.00, inclusive. The reporting person undertakes to provide Arista Networks, Inc., any security holder of Arista Networks, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
3. These shares are held in trust for the benefit of the children of the reporting person for which the reporting person serves as trustee. The reporting person shares voting and investment control over the shares but disclaims beneficial ownership of the shares.
4. These shares are held in trust for the benefit of relatives of the reporting person for which the reporting person serves as co-trustee. The reporting person shares voting and investment control over the shares but disclaims beneficial ownership of the shares.
5. These shares are held by a family trust for which the reporting person is co-trustee.
By: Isabelle Bertin-Bailly, Attorney-in-Fact For: Jayshree Ullal 07/01/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source:

FAQ

How much of RVPH does Parag Saxena currently own?

The filing cites 6,259,806 shares, representing 8.7 % of Reviva鈥檚 common stock.

Which Vedanta entity fell below the 5 % ownership threshold in RVPH?

Vedanta Associates, L.P. dropped to 4.8 % and is no longer a 5 % beneficial owner as of 27 June 2025.

Do the reporting persons disclose any recent transactions in RVPH shares?

No. Item 5(c) confirms no transactions in the past 60 days.

What is the significance of the 4.99 % blocker mentioned in the filing?

Certain warrants cannot be exercised if doing so would push ownership above 4.99 %, limiting immediate voting power increases.

What percentage of RVPH is held by Vedanta Partners, LLC?

Vedanta Partners reports 5,367,069 shares, equal to 7.5 % of outstanding common stock.
Stock ANET logo
Arista Networks Inc

NYSE:ANET

ANET Rankings

#158 Ranked by Market Cap
N/A Ranked by Dividends

ANET Latest News

Jul 1, 2025
Arista Networks Expands AI-Driven Campus and Branch Networking Offerings
May 6, 2025
Arista Networks, Inc. Reports First Quarter 2025 Financial Results
Apr 8, 2025
Arista Networks to Announce Q1 2025 Financial Results on Tuesday, May 6, 2025
Mar 12, 2025
Arista Introduces Intelligent Innovations for AI Networking
Feb 18, 2025
Arista Networks, Inc. Reports Fourth Quarter and Year End 2024 Financial Results

ANET Latest SEC Filings

Jun 30, 2025
[Form 4] Arista Networks Insider Trading Activity
Jun 27, 2025
[144] Arista Networks SEC Filing
Jun 27, 2025
[144] Arista Networks SEC Filing
Jun 26, 2025
[144] Arista Networks SEC Filing
Jun 26, 2025
[144] Arista Networks SEC Filing

ANET Stock Data

119.27B
1.03B
18.16%
68.58%
1.21%
Computer Hardware
Computer Communications Equipment
United States
SANTA CLARA